References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:https://doi.org/10.3322/caac.21254
- Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8. doi:https://doi.org/10.1038/nrc1074
- Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005;11(17):6212–7. doi:https://doi.org/10.1158/1078-0432.CCR-04-2216
- Li S, Wang A, Jiang W, Guan Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer. 2008;8(1):103–11. doi:https://doi.org/10.1186/1471-2407-8-103
- Johnston PG, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs. 2001;12(8):639–46. doi:https://doi.org/10.1097/00001813-200109000-00001
- Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136. doi:https://doi.org/10.1200/JCO.2000.18.1.136
- Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–1047. doi:https://doi.org/10.1016/S0140-6736(00)02034-1
- Sakamoto K, Maeda S. Targeting NF-κB for colorectal cancer. Exp Opin Ther Targ. 2010;14(6):593–601. doi:https://doi.org/10.1517/14728221003769903
- Du B, Jiang L, Xia Q, Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy. 2006;52(1):23–28. doi:https://doi.org/10.1159/000090238
- Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7(3):464–473. doi:https://doi.org/10.1158/1535-7163.MCT-07-2272
- Srimuangwong K, Tocharus C, Tocharus J, Suksamrarn A, Chintana PY. Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazineinduced colon cancer in rats. World J Gastroenterol. 2012;18(47):6951–6959. doi:https://doi.org/10.3748/wjg.v18.i47.6951
- Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311–335. doi:https://doi.org/10.1021/np200906s
- Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:https://doi.org/10.1124/pr.58.3.10
- Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling perturbation by natural products. Cell Signal. 2009;21(11):1541–1547. doi:https://doi.org/10.1016/j.cellsig.2009.03.009
- Neergheen VS, Bahorun T, Taylor EW, Jen LS, Aruoma OI. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology. 2010;278(2):229–241. doi:https://doi.org/10.1016/j.tox.2009.10.010
- Millimouno FM, Dong J, Yang L, Li J, Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev Res (Phila)). 2014;7(11):1081–1107. doi:https://doi.org/10.1158/1940-6207.CAPR-14-0136
- Yang Y, Zhang Z, Li S, Ye X, Li X, He K. Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis. Fitoterapia. 2014;92:133–147. doi:https://doi.org/10.1016/j.fitote.2013.10.010
- Wani ZA, Guru SK, Rao AS, Sharma S, Mahajan G, Behl A, Kumar A, Sharma PR, Kamal A, Bhushan S, Mondhe DM. A novel quinazolinone chalcone derivative induces mitochondrial dependent apoptosis and inhibits PI3K/Akt/mTOR signaling pathway in human colon cancer HCT-116 cells. Food Chem Toxicol. 2016;7:1–11.
- Han X, Shen T, Lou H. Dietary polyphenols and their biological significance. Int J Mol Sci. 2007;8(9):950–988. doi:https://doi.org/10.3390/i8090950
- Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer. 2010;62(1):1–20. doi:https://doi.org/10.1080/01635580903191585
- Lin Y-C, Tsai P-H, Lin C-Y, Cheng C-H, Lin T-H, Lee KPH, Huang K-Y, Chen S-H, Hwang J-J, Kandaswami CC, et al. Impact of flavonoids on matrix metalloproteinase secretion and invadopodia formation in highly invasive A431-III cancer cells. PLoS One. 2013;8(8):e71903. doi:https://doi.org/10.1371/journal.pone.0071903
- Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry. 2000;55(6):481–504. doi:https://doi.org/10.1016/S0031-9422(00)00235-1
- Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8(7):634–646. doi:https://doi.org/10.2174/156800908786241050
- Erdoğan MK, Geçibesler İH, Behçet L. Chemical constituents, antioxidant, antiproliferative and apoptotic effects of a new endemic Boraginaceae species: Paracaryum bingoelianum. Results Chem. 2020;2:100032. doi:https://doi.org/10.1016/j.rechem.2020.100032
- Knekt P, Jarvinen R, Seppanen R, Hellovaara M, Teppo L, Pukkala E, Aromaa A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol. 1997;146(3):223–230. doi:https://doi.org/10.1093/oxfordjournals.aje.a009257
- Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharm Ther. 2001;90(2-3):157–177. doi:https://doi.org/10.1016/S0163-7258(01)00137-1
- Neuhouser ML. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer. 2004;50(1):1–7. doi:https://doi.org/10.1207/s15327914nc5001_1
- Kanadaswami C, Lee LT, Lee PPH, Hwang JJ, Ke FC, Huang YT, Lee MT. The antitumor activities of flavonoids. In Vivo. 2005;19(5):895–909.
- Tu SH, Chen LC, Ho YS. An apple a day to prevent cancer formation: Reducing cancer risk with flavonoids. J Food Drug Anal. 2017;25(1):119–124. doi:https://doi.org/10.1016/j.jfda.2016.10.016
- Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269(2):315–325. doi:https://doi.org/10.1016/j.canlet.2008.03.046
- Kang TB, Liang MC. Studies on the inhibitory effects of quercetin on the growth of HL460 leukemia cells. Biochem Pharm. 1997;54(9):1013–1018. doi:https://doi.org/10.1016/S0006-2952(97)00260-8
- Suh DK, Lee EJ, Kim HC, Kim JH. Induction of G(1)/S phase arrest and apoptosis by quercetin in human osteosarcoma cells. Arch Pharm Res. 2010;33(5):781–785. doi:https://doi.org/10.1007/s12272-010-0519-4
- Avila MA, Velasco JA, Cansado J, Notario V. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res. 1994;54(9):2424–2428.
- Ranelletti FO, Maggiano N, Serra FG, Ricci R, Larocca LM, Lanza P, Scambia G, Fattorossi A, Capelli A, Piantelli M. Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int J Cancer. 2000;85(3):438–445. doi:https://doi.org/10.1002/(SICI)1097-0215(20000201)85:3<438::AID-IJC22>3.0.CO;2-F
- Casagrande F, Darbon JM. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001;61(10):1205–1215. doi:https://doi.org/10.1016/s0006-2952(01)00583-4
- Duraj J, Zazrivcova K, Bodo J, Sulikova M, Sedlak J. Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma. 2005;52(4):273–279.
- Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol Vitro. 2006;20(2):187–210. doi:https://doi.org/10.1016/j.tiv.2005.06.048
- Shih H, Pickwell GV, Quattrochi LC. Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer. Arc Biochem Biophys. 2000;373(1):287–294. doi:https://doi.org/10.1006/abbi.1999.1550
- Granado-Serrano AB, Martin MA, Bravo L, Goya L, Ramos S. Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr. 2006;136(11):2715–2721. doi:https://doi.org/10.1093/jn/136.11.2715
- Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther. 2007;6(9):2591–2599. doi:https://doi.org/10.1158/1535-7163.MCT-07-0001
- Chen W, Wang X, Zhuang J, Zhang L, Lin Y. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis. 2007;28(10):2114–2121. doi:https://doi.org/10.1093/carcin/bgm133
- Volate SR, Davenport DM, Muga SJ, Wargovich MJ. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis. 2005;26(8):1450–1456. doi:https://doi.org/10.1093/carcin/bgi089
- Chan TS, Galati G, Pannala AS, Rice-Evans C, O'Brien PJ. Simultaneous detection of the antioxidant and pro-oxidant activity of dietary polyphenolics in a peroxidase system. Free Rad Res. 2003;7(7):787–794.
- Attoub S, Hassan AH, Vanhoecke B, Iratni R, Takahashi T, Gaben A-M, Bracke M, Awad S, John A, Kamalboor HA, et al. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharm. 2011;651(1-3):18–25. doi:https://doi.org/10.1016/j.ejphar.2010.10.063
- Lim DY, Jeong Y, Tyner AL. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Phys Gastr Liv Phys. 2007;292(1):66–75.
- Ramos AA, Pereira-Wilson C, Collins AR. Protective effects of ursolic acid and luteolin against oxidative DNA damage include enhancement of DNA repair in Caco-2 cells. Mutat Res. 2010;692(1-2):6–11. doi:https://doi.org/10.1016/j.mrfmmm.2010.07.004
- Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. doi:https://doi.org/10.1080/01926230701320337
- Liu W, Ahmad SA, Reinmuth N, Shaheen RM, Jung YD, Fan F, Ellis LM. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis. 2000;5(4):323–328. doi:https://doi.org/10.1023/a:1009679307513
- Mantawy EM, Esmat A, El-Bakly WM, ElDin RAS, El-Demerdash E. Mechanistic clues to the protective effect of chrysin against doxorubicin-induced cardiomyopathy: plausible roles of p53, MAPK and AKT pathways. Sci Rep. 2017;7(1):1–13. doi:https://doi.org/10.1038/s41598-017-05005-9
- Frost P, Berlanger E, Mysore V, Hoang B, Shi Y, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol. 2013;2013:897025. doi:https://doi.org/10.1155/2013/897025
- Kosaka N, Sudo N, Miyamoto A, Shimizu T. Vascular endothelial growth factor (VEGF) suppresses ovarian granulosa cell apoptosis in vitro. Biochem Biophys Res Commun. 2007;363(3):733–737. doi:https://doi.org/10.1016/j.bbrc.2007.09.061
- Tian T, Nan K-J, Wang S-H, Liang X, Lu C-X, Guo H, Wang W-J, Ruan Z-P. PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis. 2010;31(7):1211–1219. doi:https://doi.org/10.1093/carcin/bgq085
- Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 2009;6(3):928–939. doi:https://doi.org/10.1021/mp800240j
- Zhao Y, Huan ML, Liu M, Cheng Y, Sun Y, Cui H, Zhou SY. Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance. Sci Rep. 2016;6:1–15.
- Erdoğan MK, Ağca CA, Aşkın H. Enhanced antiproliferative and apoptotic effects of 5-fluorouracil by combined with Pistacia eurycarpa extracts on human colorectal cancer cells. Biol Div Cons. 2019;12(1):27–38.
- Chou TC. The mass-action law based algorithms for quantitative econo-green bio-research. Integr Biol (Camb)). 2011;3(5):548–559. doi:https://doi.org/10.1039/c0ib00130a
- Chou TC, Martin N. CompuSyn software for drug combinations and for general dose effect analysis, and user’s guide. Paramus (NJ): ComboSyn, Inc; 2007.
- Erdogan MK, Ağca CA, Aşkın H. Achillea biebersteinii extracts suppress angiogenesis and enhance sensitivity to 5-fluorouracil of human colon cancer cells via the PTEN/AKT/mTOR pathway in vitro. Asian Pac J Trop Biomed. 2020;10(11):505–515. doi:https://doi.org/10.4103/2221-1691.294091
- Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 2005;5(1):12. doi:https://doi.org/10.1186/1472-6750-5-12
- Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochem Biophys Acta (BBA)-Mol Cell Res. 2013;1833(12):3448–3459. doi:https://doi.org/10.1016/j.bbamcr.2013.06.001
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi:https://doi.org/10.1006/meth.2001.1262
- Greijer AE, Van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004;57(10):1009–1014. doi:https://doi.org/10.1136/jcp.2003.015032
- Jaganathan SK, Mandal M. Honey constituents and its apoptotic effect in colon cancer cells. J Apiprod Apimed Sci. 2009;1(2):29–36. doi:https://doi.org/10.3896/IBRA.4.01.2.02
- Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, Bode AM, Dong Z. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006;66(18):9260–9269. doi:https://doi.org/10.1158/0008-5472.CAN-06-1586
- Derry MM, Raina K, Agarwal C, Agarwal R. Identifying molecular targets of lifestyle modifications in colon cancer prevention. Front Oncol. 2013;3:119. doi:https://doi.org/10.3389/fonc.2013.00119
- Ko WG, Kang TH, Lee SJ, Kim YC, Lee BH. Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells. Phytother Res. 2002;16 (3):295–298. doi:https://doi.org/10.1002/ptr.871
- Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, Lee MT. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 2001;22 (3):1615–1627.
- Wang L, Martins-Green M. Pomegranate and its components as alternative treatment for prostate cancer. Int J Mol Sci. 2014;15 (9):14949–14966. doi:https://doi.org/10.3390/ijms150914949
- Lee WJ, Wu LF, Chen WK, Wang CJ, Tseng TH. Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem Biol Interact. 2006;160 (2):123–133. doi:https://doi.org/10.1016/j.cbi.2006.01.002
- Pandurangan AK, Esa NM. Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: a review. Asian Pac J Cancer Prev. 2014;15 (14):5501–5508. doi:https://doi.org/10.7314/apjcp.2014.15.14.5501
- Ashokkumar P, Sudhandiran G. Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother. 2008;62 (9):590–597. doi:https://doi.org/10.1016/j.biopha.2008.06.031
- Ackland ML, Van De Waarsenburg S, Jones R. Synergistic antiproliferative action of the flavonols quercetin and kaempferol in cultured human cancer cell lines. In Vivo. 2005;19 (1):69–76.
- Duo J, Ying GG, Wang GW, Zhang L. Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. Mol Med Rep. 2012;5 (6):1453–1456.
- Xavier CP, Lima CF, Rohde M, Pereira-Wilson C. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother Pharmacol. 2011;68(6):1449–1457. doi:https://doi.org/10.1007/s00280-011-1641-9
- Warren CA, Paulhill KJ, Davidson LA, Lupton JR, Taddeo SS, Hong MY, Carroll RJ, Chapkin RS, Turner ND. Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis. J Nutr. 2009;139 (1):101–105. doi:https://doi.org/10.3945/jn.108.096271
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100 (1):57–70. doi:https://doi.org/10.1016/S0092-8674(00)81683-9
- Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011;145 (4):571–583. doi:https://doi.org/10.1016/j.cell.2011.03.035
- Chen C, Han Z, Yang M, Jiang Z, Ou X. Induction of apoptosis by Xiakemycin A in human hepatoma HepG2 cells. Medicine. 2020;99(17):e19848. doi:https://doi.org/10.1097/MD.0000000000019848
- Anaya-Eugenio GD, Tan CY, Rakotondraibe LH, de Blanco ECC. Tumor suppressor p53 independent apoptosis in HT-29 cells by auransterol from Penicillium aurantiacobrunneum. Biomed Pharmacother. 2020;127:110124–124. doi:https://doi.org/10.1016/j.biopha.2020.110124
- Lee Y-J, Lee Y-J, Park I-S, Song J-H, Oh M-H, Nam H-S, Cho M-K, Woo K-M, Lee S-H. Quercetin exerts preferential cytotoxic effects on malignant mesothelioma cells by inducing p53 expression, caspase-3 activation, and apoptosis. Mol Cell Toxicol. 2015;11(3):295–305. doi:https://doi.org/10.1007/s13273-015-0029-z
- Dai W, Gao Q, Qiu J, Yuan J, Wu G, Shen G. Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma. Tumour Biol. 2016;37(5):6307–6313. doi:https://doi.org/10.1007/s13277-015-4501-0
- Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16(6):2129–2144. doi:https://doi.org/10.7314/apjcp.2015.16.6.2129
- Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484. doi:https://doi.org/10.1016/j.cell.2006.01.016
- Tsang CK, Zheng XF. TOR-in(g) the nucleus. Cell Cycle. 2007;6(1):25–29. doi:https://doi.org/10.4161/cc.6.1.3675
- Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN, Jr. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(4):331–339. doi:https://doi.org/10.1038/sj.pcan.4500974
- Wright GL, Maroulakou IG, Eldridge J, Liby TL, Sridharan V, Tsichlis PN, Muise-Helmericks RC. VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. FASEB J. 2008;22(9):3264–3275. doi:https://doi.org/10.1096/fj.08-106468
- Lim W, Yang C, Bazer FW, Song G. Luteolin inhibits proliferation and induces apoptosis of human placental choriocarcinoma cells by blocking the PI3K/AKT pathway and regulating sterol regulatory element binding protein activity. Biol Reprod. 2016;95(4):82. doi:https://doi.org/10.1095/biolreprod.116.141556
- Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429 (3):403–417. doi:https://doi.org/10.1042/BJ20100323
- You Y, Wang R, Shao N, Zhi F, Yang Y. Luteolin suppresses tumor proliferation through inducing apoptosis and autophagy via MAPK activation in glioma. Onco Targets Ther. 2019;12:2383–2396. doi:https://doi.org/10.2147/OTT.S191158
- Phin S, Moore M, Cotter PD. Genomic rearrangements of PTEN in prostate cancer. Front Oncol. 2013;3:240.
- Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res. 2008;68(18):7409–7418. doi:https://doi.org/10.1158/0008-5472.CAN-08-1522
- Zhang L-L, Mu G-G, Ding Q-S, Li Y-X, Shi Y-b, Dai J-F, Yu H-G. Phosphatase and tensin homolog (PTEN) represses colon cancer progression through inhibiting paxillin transcription via PI3K/AKT/NF-κB pathway. J Biol Chem. 2015;290(24):15018–15029. doi:https://doi.org/10.1074/jbc.M115.641407
- Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213–219. doi:https://doi.org/10.2147/vhrm.2006.2.3.213
- Ahluwalia A, Jones MK, Matysiak-Budnik T, Tarnawski AS. VEGF and colon cancer growth beyond angiogenesis: does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism. Curr Pharm Des. 2014;20(7):1041–1044. doi:https://doi.org/10.2174/1381612819999131218175905
- Trinh XB, Tjalma WAA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EMJJ, Dirix LY, van Dam PA. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer. 2009;100(6):971–978. doi:https://doi.org/10.1038/sj.bjc.6604921
- Nör JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol. 1999;154(2):375–384. doi:https://doi.org/10.1016/S0002-9440(10)65284-4
- Ge YL, Zhang X, Zhang JY, Hou L, Tian RH. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int Immunopharmacol. 2009;9(4):389–395. doi:https://doi.org/10.1016/j.intimp.2008.11.020
- Byrne AM, Bouchier‐Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777–794. doi:https://doi.org/10.1111/j.1582-4934.2005.tb00379.x